Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig (ABBV-383) in Relapsed or Refractory Multiple Myeloma
NCT05650632Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2023
- Primary completion
- Aug 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of etentamig in multiple myeloma (MM) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Grade >= 2 Cytokine Release Syndrome (CRS) Events at 28 days and Number of Adverse Events (AEs) of Special Interest (CRS and Immune Effector Cell-associated Neurotoxicity Syndrome [ICANS]) at 28 days. Started Mar 2023; status: recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05650632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650632.